Plain-English translation of NCT07251023 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 3 clinical trial testing a medication called latrepirdine (also known as DMB-I or Dimebon®) in people with Alzheimer's disease. Researchers want to see if this medication can help slow memory loss and cognitive decline, and whether it works better when combined with memantine, a medication already used to treat Alzheimer's. About 450 people across 15 clinics in Russia will participate.
Current Alzheimer's treatments help some patients but are not effective enough for everyone. This medication has shown promise in early studies, and researchers want to confirm whether it can meaningfully slow cognitive decline in a large group of patients, and whether combining it with existing treatments provides additional benefit.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups: either the new medication plus memantine, a placebo plus memantine, or the new medication alone. You will take tablets by mouth three times daily. The study lasts about 56 weeks total, divided into two 26-week treatment phases. You'll visit the clinic regularly for check-ups, cognitive tests, and blood work. Your caregiver will help track your medication use and complete a patient diary at home.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Russia